Employing RNA editing to engineer personalized tumor-specific neoantigens (editopes).

Saved in:
Bibliographic Details
Title: Employing RNA editing to engineer personalized tumor-specific neoantigens (editopes).
Authors: Pecori R; Division of Immune Diversity, German Cancer Research Centre (DKFZ), Heidelberg, 69120, Germany., Casati B; Division of Immune Diversity, German Cancer Research Centre (DKFZ), Heidelberg, 69120, Germany., Merdler-Rabinowicz R; Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, United States.; Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, 5290002, Israel., Landesman N; Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, 5290002, Israel., Sanghvi K; Division of Neuroimmunology and Brain Tumor Immunology, German Cancer Research Centre (DKFZ), Heidelberg, 69120, Germany., Zens S; Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Centre (DKFZ), Heidelberg, 69120, Germany.; DKFZ Drug Discovery Lab (D3Lab), German Cancer Research Centre (DKFZ), Heidelberg, 69120, Germany., Kipfstuhl K; Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Centre (DKFZ), Heidelberg, 69120, Germany.; DKFZ Drug Discovery Lab (D3Lab), German Cancer Research Centre (DKFZ), Heidelberg, 69120, Germany., Pinamonti V; Faculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany.; BioMed X Institute, 69120 Heidelberg, Germany.; Current affiliation: Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy., Arnold A; Division of Immune Diversity, German Cancer Research Centre (DKFZ), Heidelberg, 69120, Germany., Lindner JM; BioMed X Institute, 69120 Heidelberg, Germany., Platten M; Division of Neuroimmunology and Brain Tumor Immunology, German Cancer Research Centre (DKFZ), Heidelberg, 69120, Germany.; DKTK (German Cancer Consortium) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany.; German Cancer Consortium (DKTK), DKFZ, Core Center Heidelberg, Germany.; Hertie Network of Excellence in Clinical Neuroscience.; DKFZ-Hector Cancer Institute at University Medical Center Mannheim, Mannheim, Germany.; Helmholtz Institute for Translational Oncology (HI-TRON) Mainz, German Cancer Research Center, Mainz, Germany., Offringa R; Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Centre (DKFZ), Heidelberg, 69120, Germany.; DKFZ Drug Discovery Lab (D3Lab), German Cancer Research Centre (DKFZ), Heidelberg, 69120, Germany., Carretero R; Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Centre (DKFZ), Heidelberg, 69120, Germany.; Department of Biochemistry, molecular Biology 3 and immunology. University of Granada, Spain., Ruppin E; Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, United States., Levanon EY; Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, 5290002, Israel., Papavasiliou FN; Division of Immune Diversity, German Cancer Research Centre (DKFZ), Heidelberg, 69120, Germany.
Source: BioRxiv : the preprint server for biology [bioRxiv] 2025 Nov 12. Date of Electronic Publication: 2025 Nov 12.
Publication Type: Journal Article; Preprint
Journal Info: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2692-8205
DOI:10.1101/2023.03.16.532918